Latest Headlines

Latest Headlines

PPD's X-Chem flips some potential drugs to partner Navitor

X-Chem, PPD's in-house biotech company, struck a deal with pioneering startup Navitor Pharmaceuticals, outlicensing some early-stage compounds discovered with its proprietary technology.

Calico sheds light on its R&D mission with UCSF partnership

Google's secretive Calico signed yet another partnership with a world-class research outfit, this time divulging some details that could provide clues on how it plans to attack aging.

Roche CEO Schwan flags more biopharma partnering ahead

Back at the big JP Morgan conference in San Francisco in January, Roche's big $1 billion-plus tie-up with Foundation Medicine made it clear to the most casual biopharma observer that the pharma giant plans to partner more frequently as it builds up its pipeline and expands on its diagnostics business.

Professional societies flag key areas for COPD research

The European Respiratory Society and American Thoracic Society have joined forces to highlight what we don't know about COPD in order to steer future research programs in the right way.

HK's Sihuan in partnership with Covance on drug development

Hong Kong-listed Sihuan Pharmaceutical said it has joined hands with U.S.-based Covance to develop a drug pipeline aimed at China and U.S. approvals.

Infinity pulls trigger on Takeda oncology candidate option

Infinity Pharmaceuticals exercised an option this week to purchase worldwide royalty obligations ranging from 7% to 11% on sales of duvelisib (IPI-145) in oncology indications from Takeda Pharmaceutical for $52.5 million.

Neurocrine and Mitsubishi Tanabe in license deal on Huntington's disease candidate

Nasdaq-listed Neurocrine Biosciences signed an exclusive collaboration and licensing agreement for the development and commercialization of its VMAT2 inhibitor, NBI-98854, in Japan and other select Asian markets with Mitsubishi Tanabe Pharma. The deal may lead to as much as $85 million in payments with milestones met.

Wuxi-MedImmune JV sees CFDA accept RA mAb for review

An Investigational New Drug application for WuXi PharmaTech and MedImmune's novel anti-IL6 monoclonal antibody for rheumatoid arthritis was accepted for review by the China Food and Drug Administration, the company said this week, marking a milestone in a development partnership started less than three years ago.

23andMe dives into retail with U.K. deal for personal genome service

23andMe is making its first foray into retail, teaming up with U.K. health and beauty company Superdrug to sell its genetic tests in the country.

Quintiles and Quest team up for lab testing with $575M JV

Months after LabCorp acquired its rival Covance, Quintiles has signed a sweeping agreement with lab testing giant Quest Diagnostics to launch a joint venture focused on clinical trials.